Physician profile
Philippe Tassy
NPI 1205936168
$3,335.80
in general payments reported to CMS, 2019-2025
19 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,780 · 2020: $573 · 2021: $195 · 2022: $310 · 2023: $124 · 2024: $73.70 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,070.76 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $713.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $311.11 | 2019-2021 | |
| Incyte Corporation | $310.00 | 2019-2025 | Jakafi |
| Arbor Pharmaceuticals, INC. | $263.94 | 2019-2021 | |
| Janssen Biotech, INC. | $124.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $92.24 | 2019 | |
| Celgene Corporation | $71.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.53 | 2019-2020 | |
| Lilly USA, LLC | $45.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.18 | 2019-2020 | |
| Allergan, INC. | $41.31 | 2019 | |
| Agios Pharmaceuticals, INC. | $38.14 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $30.24 | 2019-2020 | |
| Global Blood Therapeutics, INC. | $29.19 | 2020-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $27.47 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.51 | 2025 | |
| Amgen INC. | $19.97 | 2025 | Repatha, Otezla |
| Pfizer INC. | $17.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Tassy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.